Globus Medical, Inc. (GMED)
USD 72.98
(0.54%)
USD 72.98
(0.54%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 53.11 Million USD | 136.77% |
| 2022 | -144.45 Million USD | 23.17% |
| 2021 | -188.01 Million USD | 19.86% |
| 2020 | -234.59 Million USD | -21.4% |
| 2019 | -193.24 Million USD | -38.28% |
| 2018 | -139.74 Million USD | -17.62% |
| 2017 | -118.81 Million USD | 10.42% |
| 2016 | -132.63 Million USD | -120.51% |
| 2015 | -60.15 Million USD | 26.88% |
| 2014 | -82.26 Million USD | 8.56% |
| 2013 | -89.96 Million USD | 57.65% |
| 2012 | -212.4 Million USD | -48.88% |
| 2011 | -142.66 Million USD | -34.03% |
| 2010 | -106.44 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -88.2 Million USD | -173.14% |
| 2024 Q2 | 120.6 Million USD | -29.98% |
| 2024 Q1 | 172.23 Million USD | 224.28% |
| 2023 Q3 | 243.41 Million USD | 179.43% |
| 2023 Q2 | -306.45 Million USD | -40.78% |
| 2023 FY | 53.11 Million USD | 136.77% |
| 2023 Q1 | -217.68 Million USD | -50.69% |
| 2023 Q4 | 53.11 Million USD | -78.18% |
| 2022 Q3 | -134.22 Million USD | 10.98% |
| 2022 Q4 | -144.45 Million USD | -7.62% |
| 2022 FY | -144.45 Million USD | 23.17% |
| 2022 Q1 | -229.78 Million USD | -22.22% |
| 2022 Q2 | -150.77 Million USD | 34.39% |
| 2021 Q3 | -356.45 Million USD | -35.62% |
| 2021 Q4 | -188.01 Million USD | 47.25% |
| 2021 Q2 | -262.83 Million USD | -46.45% |
| 2021 FY | -188.01 Million USD | 19.86% |
| 2021 Q1 | -179.47 Million USD | 24.1% |
| 2020 Q1 | -164.96 Million USD | 15.22% |
| 2020 Q2 | -163.23 Million USD | 1.05% |
| 2020 Q3 | -247.99 Million USD | -51.93% |
| 2020 Q4 | -236.46 Million USD | 4.65% |
| 2020 FY | -234.59 Million USD | -21.4% |
| 2019 Q2 | -117.05 Million USD | 9.39% |
| 2019 Q1 | -129.17 Million USD | 7.57% |
| 2019 Q3 | -165.21 Million USD | -41.15% |
| 2019 FY | -193.24 Million USD | -38.28% |
| 2019 Q4 | -194.58 Million USD | -17.77% |
| 2018 FY | -139.74 Million USD | -17.62% |
| 2018 Q1 | -119.83 Million USD | -0.86% |
| 2018 Q4 | -139.74 Million USD | 3.82% |
| 2018 Q3 | -145.29 Million USD | -21.14% |
| 2018 Q2 | -119.94 Million USD | -0.09% |
| 2017 Q3 | -154.85 Million USD | -3.46% |
| 2017 Q1 | -182.43 Million USD | -37.54% |
| 2017 FY | -118.81 Million USD | 10.42% |
| 2017 Q4 | -118.81 Million USD | 23.27% |
| 2017 Q2 | -149.66 Million USD | 17.96% |
| 2016 Q3 | -90.19 Million USD | 5.4% |
| 2016 FY | -132.63 Million USD | -120.51% |
| 2016 Q4 | -132.63 Million USD | -47.06% |
| 2016 Q2 | -95.34 Million USD | -17.31% |
| 2016 Q1 | -81.27 Million USD | -35.12% |
| 2015 FY | -60.15 Million USD | 26.88% |
| 2015 Q3 | -50.5 Million USD | -21.52% |
| 2015 Q2 | -41.55 Million USD | 44.59% |
| 2015 Q1 | -75 Million USD | 8.82% |
| 2015 Q4 | -60.15 Million USD | -19.11% |
| 2014 FY | -82.26 Million USD | 8.56% |
| 2014 Q4 | -82.26 Million USD | 51.45% |
| 2014 Q3 | -169.44 Million USD | -24.14% |
| 2014 Q2 | -136.5 Million USD | -30.49% |
| 2014 Q1 | -104.6 Million USD | -16.27% |
| 2013 Q4 | -89.96 Million USD | 11.72% |
| 2013 FY | -89.96 Million USD | 57.65% |
| 2013 Q1 | -131.54 Million USD | 38.07% |
| 2013 Q2 | -92.31 Million USD | 29.82% |
| 2013 Q3 | -101.9 Million USD | -10.39% |
| 2012 Q4 | -212.4 Million USD | -8.84% |
| 2012 Q2 | -165.57 Million USD | -4.07% |
| 2012 Q1 | -159.09 Million USD | -11.52% |
| 2012 FY | -212.4 Million USD | -48.88% |
| 2012 Q3 | -195.15 Million USD | -17.86% |
| 2011 FY | -142.66 Million USD | -34.03% |
| 2011 Q4 | -142.66 Million USD | 0.0% |
| 2010 FY | -106.44 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott Laboratories | 8.97 Billion USD | 99.408% |
| Allurion Technologies Inc. | 3.82 Million USD | -1290.366% |
| Artivion, Inc. | 300.4 Million USD | 82.32% |
| Avanos Medical, Inc. | 121.4 Million USD | 56.25% |
| Butterfly Network, Inc. | -109.6 Million USD | 148.456% |
| Butterfly Network, Inc. | -109.6 Million USD | 148.456% |
| Bio-Rad Laboratories, Inc. | 1 Billion USD | 94.699% |
| Boston Scientific Corporation | 8.62 Billion USD | 99.384% |
| CONMED Corporation | 966.95 Million USD | 94.507% |
| Edwards Lifesciences Corporation | -449.1 Million USD | 111.826% |
| Paragon 28, Inc. | 36.39 Million USD | -45.948% |
| Glaukos Corporation | 290.27 Million USD | 81.703% |
| Inspire Medical Systems, Inc. | -160.69 Million USD | 133.052% |
| Integer Holdings Corporation | 1.01 Billion USD | 94.779% |
| Medtronic plc | 24.76 Billion USD | 99.786% |
| Myomo, Inc. | -6.27 Million USD | 947.081% |
| Nevro Corp. | 117.61 Million USD | 54.841% |
| Owlet, Inc. | -1.34 Million USD | 4060.629% |
| Penumbra, Inc. | 66.85 Million USD | 20.559% |
| Vicarious Surgical Inc. | -37.99 Million USD | 239.805% |
| Smith & Nephew plc | 2.78 Billion USD | 98.091% |
| Sonendo, Inc. | 26.34 Million USD | -101.625% |
| STERIS plc | 3.17 Billion USD | 98.328% |
| Stryker Corporation | 10.02 Billion USD | 99.47% |
| Vapotherm, Inc. | 102.66 Million USD | 48.268% |
| Zimmer Biomet Holdings, Inc. | 5.57 Billion USD | 99.048% |